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Abstract 
This review aims at summarizing the present knowledge on the clinical consequences of concomitant coeliac disease 
(CD) in adult patients with type 1 diabetes mellitus (T1DM). The cause of the increased prevalence of CD in T1DM 
patients is a combination of genetic and environmental factors. Current screening guidelines for CD in adult T1DM 
patients are not uniform. Based on the current evidence of effects of CD on bone mineral density, diabetic complica-
tions, quality of life, morbidity and mortality in patients with T1DM, we advise periodic screening for CD in adult T1DM 
patients to prevent delay in CD diagnosis and subsequent CD and/or T1DM related complications.
Keywords: Coeliac disease, Clinical characteristics, Gluten free diet, Screening, Quality of life, Tissue-transglutaminase 
antibodies, Complications and type 1 diabetes mellitus
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Coeliac disease (CD) is a permanent intolerance to 
ingested gluten resulting in immune mediated inflam-
matory damage to the small intestinal mucosa and a sub-
sequent malabsorption syndrome [1]. Diagnosis of CD 
requires duodenal biopsy when the patient is on a gluten-
containing diet and for the vast majority of adult patients 
also positive serology [2]. CD is one of the commonest 
lifelong disorders encountered in Western countries with 
a prevalence of about 0.6 % in the general population [3] 
and is, in particular in genetically susceptible individu-
als, associated with other autoimmune disorders includ-
ing type 1 diabetes mellitus (T1DM) and autoimmune 
thyroiditis [4]. T1DM is characterized by T-cell mediated 
destruction of the insulin-producing β-cells in the pan-
creas leading to hyperglycaemia and diabetic ketoacidosis 
[5]. Diabetes is diagnosed based on 1) plasma glucose cri-
teria, either the fasting plasma glucose (FPG) or the 2-h 
plasma glucose (2-h PG) value after a 75-g oral glucose 
tolerance test (OGTT) or 2) on a glycated haemoglobin 
(HbA1c) value of >6.5  % [6]. Long term diabetic com-
plications consist of micro- and macrovascular disease, 
which account for the major morbidity and mortality 
associated with T1DM [7]. Up to one-third of patients 
with T1DM have thyroid antibodies, and half of these 
patients may progress to clinical autoimmune thyroid 
disease [8]. The need for annual screening for thyroid dis-
ease in T1DM patients has therefore been recommended.
The over all prevalence of CD in T1DM patients is 
about 6  % [9]. The association between CD and T1DM 
was first noted over 40 years ago in children [10]. There-
fore, screening in paediatric T1DM patients is advocated. 
However, international paediatric consensus based guide-
lines differ in the need and frequency of screening for 
CD [11]. Some recommend an annual screening interval 
by testing antibodies against tissue transglutaminase 2 
(TG2A), others advice to perform these tests in the pres-
ence of typical CD symptoms only [11]. However, despite 
the high prevalence of CD in T1DM patients there is no 
consensus on screening adult T1DM patients for CD.
In this review it is discussed whether screening for 
CD should be performed in adult T1DM patients and at 
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was screened with respect to the clinical features of 




T1DM and CD are auto-immune, inflammatory diseases 
for which the major genetic contribution arises from the 
major histocompatibility complex [12]. These so-called 
HLA-DQ heterodimers enable the presentation of pep-
tides that are derived from otherwise innocuous self- or 
non-self antigens (proteins from insulin producing beta 
cells in T1DM, gliadins in CD) and activate pathogenic 
effector T-cells [13]. Besides the genetic overlap in the 
major histocompatibility complex, genome wide associa-
tion studies (GWAS) in these two diseases have revealed 
a large number of well validated, non-HLA genetic risk 
loci providing an opportunity to explore the possibility of 
overlapping susceptibility between them [12].
Thus, genetic overlap exists between CD and T1DM 
consisting of both HLA and non-HLA genes [14–16]. 
Both disorders are associated with the major histocom-
patibility complex (MHC) class 2 antigen DQ encoded 
by the alleles DQA1*05 with DQB1*02 (DQ2.5) and 
DQA1*03 with DQB1*03:02 (DQ8) [1, 17].
In patients with CD, individuals who are HLA-DQ 2.5 
homozygous have a greater risk of developing CD and 
the gluten specific T-cell response is more vigorous when 
gluten peptides are presented by antigen presenting cells 
homozygous for HLA-DQ 2.5 [18, 19]. In European Cau-
casian populations, more than 90 % of CD patients carry 
the HLA-DQ 2.5 heterodimer and the majority of CD 
patients who do not carry this HLA-DQ 2.5 heterodimer 
are HLA-DQ8 or HLA-DQ2.2 positive [20].
The main determinant of risk of developing T1DM is 
HLA-DQ8 and to a lesser extent HLA-DQ 2.5 [21, 22]. 
In a recent study, we compared the frequency of HLA-
DQ haplotypes between 2472 T1DM patients versus 483 
T1DM + CD patients [16]. In patients with T1DM, the 
HLA-DQ 2.5 haplotype showed a significant associa-
tion and provided the highest risk for developing double 
autoimmunity (OR = 1.44, p-value = 0.0003, Table 1). As 
expected, the absence of the haplotypes HLA-DQ 2.5, 
DQ8 and DQ 2.2 (which is classified as “other” which is 
present in about 25  % of T1DM patients), showed the 
strongest protection (OR  =  0.66, p  =  0.0001, Table  1). 
Therefore, an HLA-DQ 2.5 negative T1DM patient does 
not require monitoring for CD.
In addition to the overlap between T1DM and CD in 
HLA genes, it was revealed that non-HLA genes over-
lap as well [12, 16]. CTLA-4 and IL2RA loci are more 
strongly associated with double autoimmunity than with 
either T1DM or CD alone [16]. The combination of HLA 
and non-HLA variants might improve risk prediction for 
potential CD [23].
Environmental factors
Several environmental factors have been investigated as 
precipitating factors for the development of T1DM or CD. 
A popular theory, based on possible molecular mimicry, 
is the association between autoimmune diseases and viral 
infections. Prime viral candidates that have been shown 
to cause precipitation to T1DM are enteroviruses, more 
specifically Coxsackie viruses [24]. Moreover, rotavirus 
infection increases the risk for developing T1DM and an 
association between rotavirus and increased risk for CD 
has been described as well [25, 26]. Furthermore, an altered 
composition of bacteria in the gut, altered gut perme-
ability and intestinal inflammation seem to be factors that 
contribute to the development of T1DM [27]. Exposure to 
cereals has been described as a risk factor for the develop-
ment of both T1DM and CD related autoantibodies. How-
ever, these studies show conflicting results [28–30].
Demographic characteristics
Epidemiology
Many studies have investigated the prevalence of CD in 
paediatric and adult T1DM patients by different serologi-
cal screening methods (gliadin, anti endomysium (EMA), 
anti tissue transglutaminase (TG2A) and anti reticulin 
antibodies). The prevalence of CD in T1DM patients 
(children and/or adults) is reported to vary between 0.8 % 
and 16.4  % with a mean prevalence of 6  % [4, 9, 31]. A 
large meta-analysis identified 27 studies, which included 
in total 26 605 individuals with T1DM [9]. Seventeen 
studies were performed in Europe, 4 in North America, 
1 in South America, 1 in Australia, 3 in the Middle East 
and 1 in India (Fig. 1) [9]. A remarkable high prevalence 
of CD in T1DM patients is seen in studies performed in 
Algeria (16.4 %), India (11.1 %) and Saudi Arabia (11.3 %) 
[32–34]. The relatively high frequency of HLA-DQ 2.5 
in the Middle East and India possibly contributes to 
the high prevalence of CD in T1DM [35]. Furthermore, 
these countries have a per capita wheat consumption 
that ranks among the highest in the world [35]. This high 
prevalence still needs to be confirmed in additional stud-
ies. Data from East-Asian and African T1DM cohorts 
and CD screening are lacking in current literature.
Clinical presentation
The clinical presentation of CD in T1DM patients resem-
bles that in non-T1DM patients and consists of gastro-
intestinal complaints (diarrhoea, constipation, vomiting, 
abdominal distension, anorexia) or extra-intestinal com-
plaints such as growth failure, anaemia, decreased bone 
mass or osteoporosis, and dental enamel defects [4]. 
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However, CD patients might also be asymptomatic and 
may have subtle complaints indicative of CD and may 
only be recognized in retrospect following the benefits of 
a GFD [36]. Previous studies have reported that 45–60 % 
of patients with T1DM and CD did not have any com-
plaints of CD indicating a diagnostic challenge [37, 38].
Furthermore, gastrointestinal complaints are com-
mon in T1DM patients and a broad differential diagnosis 
exists for these patients (Table 2) [39, 40]. Furthermore, 
the fact that a large part of patients presents only with 
mild symptoms or seem to be asymptomatic provides dif-
ficulties for detecting CD [41]. Often, a reduced health 
is only recognized retrospectively, following the benefits 
conferred to a GFD [36].
It has been demonstrated that the risk of CD in T1DM 
patients is associated with age of onset of T1DM. Chil-
dren with age of onset of T1DM younger than 4 years are 
at higher risk to develop CD than those with older age 
of onset [42]. Regarding clinical practice, we observed 
two peaks in the age of CD diagnosis in T1DM patients: 
Table 1 Haplotype and genotype HLA association and frequency comparison between double autoimmunity versus type 
1 diabetes-only [16]
CD coeliac disease, OR Odd’s ratio, T1DM type 1 diabetes mellitus
T1DM + CD versus T1DM OR (CI 95 %) p value
Frequency controls Frequency T1DM + CD Frequency T1DM only
Haplotype
DQ 2.5 0.14 0.446 0.318 1.442 (1.189, 1.748) 0.0003
DQ 2.2 0.094 0.046 0.040 1.201 (0.793, 1.821) 0.381
DQ8 0.1 0.346 0.392 0.939 (0.779, 1.131) 0.520
Other 0.663 0.163 0.249 0.660 (0.530, 0.821) 0.0001
Genotype
DQ 2.5/DQ 2.5 0.020 0.168 0.066 1.20 (1.14, 1.26) 0.0005
DQ 2.5/DQ 2.2 0.032 0.039 0.017 1.16 (1.06, 1.27) 0.242
DQ 2.5/DQ8 0.027 0.350 0.377 0.98 (0.95, 1.01) 0.681
DQ 2.5/other 0.184 0.168 0.112 1.07 (1.03, 1.11) 0.688
DQ 2.2/DQ 2.2 0.012 0.004 0.002 1.18 (0.88, 1.58) 0.169
DQ 2.2/DQ 8 0.022 0.033 0.036 0.98 (0.92, 1.06) 0.908
DQ 2.2/Other 0.111 0.010 0.025 0.91 (0.83, 0.99) 0.326
DQ 8/DQ 8 0.009 0.083 0.078 1.00 (0.96, 1.05) 0.886
DQ 8/Other 0.135 0.143 0.216 0.94 (0.91, 0.97) 0.175




























































Fig. 1 Mean prevalence of screen detected coeliac disease (CD) in 
children and adults with type 1 diabetes mellitus (T1DM) around the 
world. Mean prevalence is calculated from studies with at least 100 
patients with T1DM [9]. N indicates the number of screening studies 
performed on each continent
Table 2 Differential diagnosis of  gastrointestinal com-
plaints in T1DM patients [39, 40, 105, 106]
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around 10 and 45 years of age [41]. T1DM diagnosis pre-
cedes CD diagnosis in about 90 % of patients and females 
with T1DM have a higher risk of the additional diagnosis 
of CD than males [41, 42].
A new syndrome of gluten intolerance, non coeliac glu-
ten sensitivity (NCGS), has been described. NCGS can be 
diagnosed in those patients with gluten intolerance who 
do not develop antibodies that are typical neither of CD 
nor of wheat allergy and who do not suffer from lesions 
in the duodenal mucosa [43]. Although disease charac-
teristics of NCGS are overlapping with irritable bowel 
syndrome (IBS), a recent study observed that an associ-
ated autoimmune disease was present in 14 % of patients 
with NCGS, which was mainly autoimmune thyroiditis 
and sporadically T1DM [44].
Adherence to a GFD
Nutrition therapy is an important issue in the manage-
ment of T1DM and the cornerstone of treatment in 
patients with CD [6, 45].
In T1DM, dietary interventions aim to maintain blood 
glucose, blood pressure, lipid levels and body mass index 
in the normal range [46]. A GFD together with an insulin 
therapy integrated into an individual’s dietary and physi-
cal activity pattern imposes practical limitations and leads 
to restrictions in the lifestyle of a child or adolescent. 
Therefore, it may not be surprising that non adherence to 
a GFD in T1DM patients with CD is more common than 
in CD patients [47, 48]. Another problem that arises is the 
availability of gluten free food. In 5 different US states it 
was found to be significantly less available than food con-
taining gluten [49]. The increased cost of GFD products 
may have an impact on compliance in T1DM patients 
with CD as well [49]. Therefore, we advise that patients 
with both conditions are guided by a skilled dietitian.
Clinical consequences of CD in adult patients 
with T1DM
So far, studies addressing the consequences of CD in 
adult T1DM patients differ in methodology, study size 
and prospective/retrospective design. Therefore, these 
results are difficult to compare and interpret. An over-
view of these results is given in Table 3.
Glycaemic control
In adult patients with T1DM, no significant change of 
HbA1c levels was found, when comparing before CD 
diagnosis, at CD diagnosis and after treatment of CD by 
a GFD [50, 51]. This data is confirmed in a recent pop-
ulation based cohort study which found that having a 
diagnosis of CD does not influence the risk of hospital 
admission due to hypoglycaemia, keto-acidosis or coma 
in T1DM patients [52].
Lipid profile
Undetected CD in the general population is associated 
with lower cholesterol levels, which is thought to contrib-
ute to a favourable cardiovascular risk profile in untreated 
CD patients [53]. Accordingly, lower levels of cholesterol 
and triglycerides were found in newly detected, untreated 
CD patients with T1DM [54]. The assumed mechanism 
that may contribute to the lower cholesterol levels in 
undetected CD patients is malabsorption.
Microvascular complications
Intensive insulin therapy to normalize blood glucose lev-
els effectively delays the onset and slows the progression 
of microvascular complications including diabetic retin-
opathy, nephropathy and neuropathy in T1DM patients 
[55–57]. Several studies investigated the influence of 
(newly diagnosed) CD with or without treatment by a 
GFD on long term diabetic complications and found CD 
to be either protective [51, 54, 58] or aggravating [59–61]. 
A recent large nationwide study in Sweden revealed that 
the duration of CD is important for the eventual effect 
[60]. They showed that individuals with T1DM and CD 
were at a lower  risk of  diabetic retinopathy in the first 
5  years after CD diagnosis (adjusted hazard ratio (HR) 
0.57 [95  % CI 0.36–0.91]), followed by a neutral risk in 
years 5 to <10 years (1.03 [0.68–1.57]). With longer fol-
low-up, coexisting CD was a risk factor for diabetic retin-
opathy (10 to <15  years of follow-up, adjusted HR 2.83 
[95 % CI 1.95–4.11]; ≥15 years of follow-up, 3.01 [1.43–
6.32]) [60]. They ascribe the protective effect in the first 
5 years to lower cholesterol levels and lower body mass 
index (BMI). However, this study lacks individual-based 
information on GFD adherence.
In a study of our group we found less diabetic retinopa-
thy in a T1DM population with a mean CD duration of 
3 years+ treatment by GFD compared to T1DM patients 
without CD [51]. Also, a previous study by Pitocco 
et  al. showed more subclinical atherosclerosis in T1DM 
patients with a mean duration of treated CD of 9.9 years 
[61]. These studies suggest that a short duration of CD 
is protective and a longer duration of CD may aggravate 
diabetic complications [51, 60].
Renal disease
CD is associated with a higher risk of end-stage renal 
disease (ESRD) with a Hazard Ratio (HR) for ESRD of 
2.87 (95 % CI 2.22 to 3.71, p < 0.001) [62]. The cumula-
tive prevalence of end-stage renal disease in T1DM 
patients without CD, is 2.2  % at 20  years and 7.7  % at 
30 years [63]. Interestingly, in T1DM patients with CD it 
was found that non-adherence to a GFD was associated 
with early elevation of albumin excretion in urine, a rec-
ognized factor for diabetic nephropathy [64]. Skovbjerg 
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et al. found that there was a higher prevalence of CD in 
T1DM patients with nephropathy (2.6 %) than in T1DM 
patients without nephropathy (1 %) [65]. A recent study 
found a positive association between longstanding CD in 
T1DM patients and chronic renal disease in T1DM [66]. 
For chronic renal disease, this excess risk was present 
after more than 10 years of CD (HR 2.03, 95 % CI 1.08, 
3.79) [66]. However, data about GFD adherence was lack-
ing. These studies suggest that concomitant CD in T1DM 
patients might lead to more nephropathy in case of long-
standing CD, in particular in case of poor adherence to a 
GFD [64]. The underlying mechanisms need, however, to 
be elucidated.
Bone mineral density
Decreased bone mineral density (BMD) is observed 
both in T1DM patients [67] and in CD patients [68]. In 
the latter group of patients, this is especially related to 
the intestinal malabsorption of vitamin D, necessary 
for healthy bone metabolism [68]. Reports have shown 
that bone mineral density is lower in paediatric T1DM 
patients with undiagnosed CD than in T1DM patients 
without CD [69, 70]. As expected, also in adults with 
both T1DM and active CD, a decreased BMD was found, 
but whether CD or T1DM was the cause remains unclear 
[71]. A study by Sategna-Guidetti showed that treatment 
by a GFD results in an improvement of lumbar spine 
BMD in adults with CD [72].
In summary, BMD in T1DM + CD patients is generally 
decreased and follow-up of BMD with possible treatment 
is warranted. Besides maintaining a GFD, data is scarce 
whether calcium and vitamin D supplementation in CD 
patients is mandatory [68]. Lifestyle changes as regular 
exercise and smoking cessation should be advised, and in 
the case of osteoporosis, calcium, vitamin D and bisphos-
phonates should be prescribed [68].
Quality of life
Both T1DM and CD are chronic illnesses which influ-
ence the quality of life (QOL) since the treatments are 
burdensome and the complications can be debilitating 
and life threatening. T1DM patients have a diminished 
QOL which is partly caused by the development of vas-
cular complications [73]. The lower QOL in CD patients 
is reported especially in the social aspects of life and in 
those with symptoms, women being mostly affected [74]. 
In adult T1DM patients with both T1DM and treated 
CD, we described a compromised QOL particularly in 
women and both social functioning and general health 
perception was affected [75]. This is of importance since 
patients with T1DM are at increased risk of depression 
[76]. The additional diagnosis of CD further increases the 
Table 3 Clinical consequences of  coeliac disease (CD) in  adult Type 1 Diabetes Mellitus (T1DM) patients as  compared 
to T1DM without CD
?, no studies performed; NA, not applicable
Clinical consequence T1DM + CD Patients on GFD References
HbA1c Hba1c in screen detected CD patients is lower  




No difference in HbA1c during follow up Yes [51]
Yes [54]
No increased risk for hospital admission due to hypoglycaemia, keto-
acidosis or coma
Unknown [52]
Cholesterol + triglycerides Lower in screen detected CD patients NA [59]
NA [54]
Nephropathy Higher prevalence of nephropathy Unknown [65]
Unknown [64]
Retinopathy <10 years of CD results in less retinopathy, more than  
10 years leads to more retinopathy
Unknown [60]
Yes [51]
Bone mineral density Lower BMD at diagnosis NA [71]
Quality of life Decrease, particularly in women, both social functioning  
and general health perception are affected
Yes [75]
Depression Increased risk Unknown [77]
Refractory Coeliac disease ? ?
Enteropathy associated T cell lymphoma ? ?
Mortality A diagnosis of CD for >15 years increases the risk of death in patients 
with T1D
Unknown [82]
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risk of depression, and this should be taken into account 
in the clinical support of these patients [77].
Comorbidity and mortality
T1DM is, beside CD, associated with autoimmune thy-
roid diseases (Hashimoto’s or Graves’ disease) (AIT), 
autoimmune gastritis, Addison’s disease, and vitiligo 
[8]. The presence of a third autoimmune disease in 
T1DM  +  CD patients is frequently found. A study by 
Kaspers et al. found a higher incidence of AIT in patients 
with T1DM and CD (6.3  %) when compared to those 
with CD alone (2.3 %) [78]. Our clinical practice study in 
adults revealed that 28 % of T1DM + CD patients were 
diagnosed with a third autoimmune disease, mainly auto-
immune thyroiditis (22 %) [79].
A small group of patients with CD fail to improve clini-
cally and histologically upon elimination of dietary gluten 
and this complication is referred to as refractory coeliac 
disease (RCD) [80]. RCD imposes a serious risk of devel-
oping enteropathy-associated T-cell lymphoma (EATL). 
The prevalence of RCD and EATL in the general popu-
lation is very rare and studies investigating the risk of 
developing RCD or malignancy in T1DM + CD patients 
are currently lacking [81].
The question whether CD influences the mortality 
in T1DM patients was recently investigated in Sweden 
[82]. These authors described that having a CD diagno-
sis for more than 15 years was associated with a 2.8-fold 
increased risk of death in individuals with T1DM [82]. 
They hypothesized that the excess mortality was caused 
by persistent low grade inflammation due to CD or poor 
adherence to a GFD while using insulin therapy.
Rationale for screening for CD in adult T1DM 
patients
CD fulfills many of the WHO criteria for screening 
in patients with T1DM but not all of them [83]. CD 
is common and well defined, screening tests are sim-
ple +  safe +  accurate, screening seems to be culturally 
acceptable, treatment is available and clinical detection of 
CD can be difficult. However, studies are lacking whether 
screening for CD in T1DM patients is cost effective and 
it is currently unknown whether screen detected asymp-
tomatic CD patients benefit from starting with a GFD. 
The latter will be investigated by the CD-DIET study 
[84] which is designed as a prospective controlled trial in 
which asymptomatic screen detected CD patients will be 
treated with or without a GFD. The results of the efficacy 
and safety of a GFD in patients with T1DM with asymp-
tomatic CD will add significant data to the discussion 
about screening for CD in T1DM patients [84].
Consequently, there is still no consensus on screen-
ing adult patients with T1DM for CD. International 
guidelines for adult CD and T1DM differ in their recom-
mendations for screening of CD in T1DM patients [2, 6, 
85–91] (Table 4). At present, a case-finding approach in 
adult T1DM patients is most acceptable, ethically and 
financially [2, 92]. However, a recent study in the United 
States and Canada underscores the need for an uniform 
screening program. This study revealed a high variabil-
ity in testing for CD in T1DM patients together with an 
inconsistency of management of CD [93]. In addition, 
we have recently reported that approximately 20  % of 
patients with T1DM and CD reported to have had CD 
related complaints for at least 5  years before CD diag-
nosis was made [79]. The long term consequences of a 
diagnostic delay are currently unknown. The high preva-
lence of several complications as reported in Table  3 in 
T1DM  +  CD patients, together with improvement of 
BMD after start of a GFD provides a strong rationale 
for an uniform screening program together with careful 
monitoring. Further, a recent randomized study showed 
that screen-detected and apparently asymptomatic EmA-
positive patients at risk for CD benefit from a GFD as 
measured by extensive clinical, serologic, and histo-
logic parameters [94]. Hypothetically, this data might 
be extrapolated to asymptomatic CD in T1DM patients. 
Another argument for screening is the fact that the inci-
dence of T1DM and CD is rising over time [95, 96].
We propose the following screening algorithm (Fig. 2) 
for CD in adult T1DM patients. CD should be diagnosed 
by serology and duodenal biopsy with the patient on a 
gluten-containing diet [2]. Serology is by TG2A and if 
patients are IgA deficient, IgG-TG2A can be used. Villous 
atrophy (Marsh IIIa- IIIc) is required for diagnosis of CD 
[2]. Due to the high sensitivity and specificity of TG2A, 
this test is used for screening in T1DM patients [97]. In 
case of IgA deficient individuals, or in patients with high 
probability of CD, IgG TG2A should be tested as 2  % 
of CD patients are IgA deficient [2]. As T1DM patients 
might have transient elevations of TG2A, a confirma-
tory small intestinal biopsy is recommended [98, 99]. In 
case of a biopsy with Marsh I-II, a serological repetition 
in 5  year is recommended. Further, another differential 
diagnosis for intraepithelial lymphocytosis should be 
considered (e.g. Giardia, olmesartan induced, small intes-
tinal bacterial overgrowth). So far, only retrospective data 
is available and prospective studies are needed to deter-
mine a screening interval for CD in T1DM patients. As 
proposed by DeMelo et  al. [100], we suggest to repeat 
TG2A testing every 5  years in case of negative serol-
ogy. A recent systematic review found that most cases of 
CD are diagnosed within 5  years of T1D  diagnosis and 
they advise screening at T1D diagnosis and within 2 and 
5  years thereafter [101]. Only the Australian Diabetes 
Society recommends screening for CD after 5  years of 
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T1DM diagnosis (Table 4). As studies are lacking inves-
tigating the screening frequency in T1DM patients, we 
advocate continuing screening every 5  years for CD in 
T1DM patients. In the presence of CD a clinical work-
up should be performed to evaluate and possibly treat 
bone mineral density and vitamin deficiencies (Fig.  2). 
Based on current data, this screening algorithm is not 
applicable to all countries as studies about prevalence of 
CD in T1DM patients are lacking from several countries 
(Fig. 1).
Table 4 Clinical recommendations for screening of CD in T1DM patients in adult CD and T1DM guidelines
BMI body mass index, CD coeliac disease, T1DM Type 1 diabetes mellitus
Guidelines Years Recommendation Reference
CD guidelines
 Gastroenterological Society of Australia 2007 Not reported [85]
 Dutch Society of Gastroenterology 2008 Testing for CD in case of clinical suspicion [86]
 World Gastroenterology Organisation 2013 Not reported [88]
 American College of Gastroenterology 2013 Testing for CD if there are any digestive symptoms, or signs,  
or laboratory evidence suggestive of CD
[89]
 British Society of Gastroenterology 2014 Testing for CD should be performed when CD is suspected [2]
 National Institute for Health and Care Excellence 
(NICE)




 American Diabetes Association 2014 Screening for CD soon after T1DM diagnosis, thereafter screening  
should be considered based on signs and symptoms
[6]
 National Institute for Health and Care Excellence 
(NICE)
2015 In case of low BMI or weight loss, screen for CD [87]
 Australian Diabetes Society 2011 Screen for CD at diagnosis and at least in the first five years after diagnosis [91]
Fig. 2 Proposed algorithm for the screening and follow-up of coeliac disease (CD) in asymptomatic patients with type 1 diabetes mellitus (T1DM). 
DXA dual X-ray absorptiometry, GFD gluten free diet, GDS gastroduodenoscopy, TG2A tissue transglutaminase 2 antibodies. 1 IgA TG2A should be 
evaluated first, in IgA deficient individuals or in patients with high probability of CD IgG TG2A should be performed
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HLA‑DQ typing
The European Society for Paediatric Gastroenterol-
ogy, Hepatology and Nutrition (ESPGHAN) guidelines 
recommend assessing the HLA-DQ2.5/DQ8 genotype 
in patients with T1DM, as an initial approach for CD 
screening. A recent study investigated the clinical rel-
evance and cost-effectiveness of human leukocyte anti-
gen (HLA)-genotyping in T1DM patients as a screening 
tool   [102]. They found that HLA-DQ typing in T1DM 
patients is neither distinctive nor cost-effective in screen-
ing for CD [102]. This might be due to the fact that only 
25  % of T1DM patients is HLA-DQ 2.5 or DQ 8 nega-
tive [14, 16]. Thus, in our algorithm HLA-DQ typing is 
excluded.
According to recent guidelines for symptomatic chil-
dren who have high antibody titres, a duodenal biopsy 
is not needed anymore for diagnosing CD [103]. Indeed, 
a recent study showed that none of the T1DM children 
with high TG2A titres would have needed a biopsy for 
diagnosis [104]. Whether this is also the case in symp-
tomatic adult T1DM patients with high TG2A titres 
remains to be established.
Conclusions
CD fulfills many of the WHO criteria for screening as it 
is common, simple to diagnose, and treatment is avail-
able. Detection of CD in T1DM patients is important 
as morbidity and mortality is increased in patients with 
both T1DM and CD. Furthermore, several clinical con-
sequences are present in both disorders as decreased 
BMD, nephropathy, retinopathy and decreased QOL 
which need careful follow-up. We propose an algorithm 
for periodic screening and advise a multidisciplinary 
approach for these complex patients.
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